Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
- Author:
Bhumsuk KEAM
1
;
Dong Wan KIM
;
Jin Hyun PARK
;
Jeong Ok LEE
;
Tae Min KIM
;
Se Hoon LEE
;
Doo Hyun CHUNG
;
Dae Seog HEO
Author Information
- Publication Type:Original Article
- Keywords: Nomograms; Lung neoplasms; Epidermal growth factor receptor; Tyrosine kinase inhibitor; Prognosis
- MeSH: Calibration; Carcinoma, Non-Small-Cell Lung*; Drug Therapy; Humans; Lung Neoplasms; Neoplasm Metastasis; Nomograms*; Prognosis; Protein-Tyrosine Kinases*; Receptor, Epidermal Growth Factor*
- From:Cancer Research and Treatment 2014;46(4):323-330
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aim of this study was to develop a pragmatic nomogram for prediction of progressionfree survival (PFS) for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A total of 306 recurred or metastatic NSCLC patients with EGFR mutation, who received EGFR TKIs, were enrolled in this study. We developed the nomogram, using a Cox proportional hazard regression model for PFS. RESULTS: The median PFS was 11.2 months. Response rate to EGFR TKI was 71.9%. Multivariate Cox model identified disease status, performance status, chemotherapy line, response to EGFR TKI, and bone metastasis as independent prognostic factors, and the nomogram for PFS was developed, based on these covariates. The concordance index for a nomogram was 0.708, and the calibration was also good. CONCLUSION: We developed a nomogram, based on clinical characteristics, for prediction of the PFS to EGFR TKI in NSCLC patients with EGFR mutation.
